- The Chinese biopharmaceutical industry is transitioning from traditional batch production to continuous manufacturing to enhance efficiency and global competitiveness.
- A recent summit highlighted this shift, with Sartorius emphasizing the need for stable and compliant production processes to meet international regulatory standards.
- Continuous manufacturing is projected to grow significantly, offering reduced costs and improved product quality, while Sartorius aims to support local companies in adapting to this new paradigm.
